Published on March 3, 2010 at 8:12 AM
Pfizer Inc. (NYSE: PFE) and Medivation, Inc. (NASDAQ: MDVN) today
announced results from two Phase 3 trials of the investigational
drug dimebon (latrepirdine) in patients with Alzheimer’s disease (AD).
In the CONNECTION trial, dimebon did not meet its co-primary or
secondary efficacy endpoints compared to placebo. Co-primary endpoints
were measures of cognition and global function.
“We recognize the significant medical need, and we are committed to
advancing treatment options for Alzheimer’s disease.”
“The results from the CONNECTION study are unexpected, and we are
disappointed for the Alzheimer’s community,” said Dr. David Hung,
president and chief executive officer of Medivation. “We are working
with our colleagues at Pfizer to better understand the CONNECTION data
and we plan to present these data at an upcoming medical meeting.”
Dimebon was well tolerated in both the CONNECTION study and in a
separate Phase 3 safety and tolerability study, which confirmed
dimebon’s tolerability when dosed alone or in combination with approved
Alzheimer’s disease medicines.
“We are evaluating the CONNECTION data with Medivation. After that
review, Pfizer will be in a position to determine appropriate next steps
regarding the dimebon program,” said Dr. Briggs W. Morrison, senior vice
president, clinical development, Primary Care Business Unit at Pfizer.
“We recognize the significant medical need, and we are committed to
advancing treatment options for Alzheimer’s disease."
Source Pfizer Inc. and Medivation, Inc.